NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with more than 1400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and well-tolerated in the study; no new safety and tolerability signals were identified.
Extended treatment intervals with bevacizumab preserved vision of many patients with high baseline vision.
The company announced it will share clinical data at Eyecelerator and the American Society of Cataract and Refractive Surgery 2024 Annual Meeting in Boston.
The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.
According to the company, EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.
One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.
Phentolamine ophthalmic solution 0.75% is a preservative-free, stable eye drop, which blocks the α1 receptor within the iris dilator muscle without affecting the ciliary muscle.
According to the company, MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events.
Patients can experience solar retinopathy after viewing the eclipse without protection, but it also can occur from outdoor activities, including those mentioned. It can lead to symptoms that include blurry vision, vision loss at the center of a patient’s sight and eye pain.
The effort led to the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae.
The audiobook of GRF's flagship 40-page educational booklet "Understanding and Living with Glaucoma is narrated by Bianca Beach, an actress, advocate, and glaucoma patient.
While the change is mostly a result of improved recognition of in situ cases, authors wanted to identify any changes in the incidence and mortality of conjunctival melanoma in Australia from 1982 to 2014.
Yehia Hashad, executive vice president, research and development, and Chief Medical Officer at Bausch + Lomb sat down with David Hutton of Ophthalmology Times to talk about the upcoming solar eclipse and what ophthalmologists can do to promote safe viewing of the event for their patients.
Explore cutting-edge ophthalmology innovations in this new series on the Ophthalmology Times EyePod podcast. Throughout this series, we'll hear insights from various stakeholders in clinical practice, academia, and industry. In this episode, host Ehsan Sadri, MD, engages in a conversation with Jeffry Weinhuff, managing partner at Visionary Ventures, exploring trends and offering advice for individuals driven by an entrepreneurial mindset.
A new Provectus spinout company would commercialize combination therapy of the university’s light source medical device and its pharmaceutical-grade rose bengal sodium.
The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
Following the CRL from the FDA last year, Aldeyra is planning to initiate a dry eye chamber clinical trial in the first half of 2024.
Ocular toxicity from breast cancer chemotherapy, head and neck cancer radiation and targeted therapy.
The Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine recently received a $1 million donation to drive its efforts to successfully transplant a whole eye.
The company announced it has entered into a global licensing agreement with ForSeeCon Eye Corp. for the company's ophthalmology pipeline, which includes the medical device Vitargus.
Kay Durairaj, MD, FACS, known as Dr Kay, discusses blepharoplasty and the collaboration between facial plastic surgeons and ophthalmologists in a conversation with Ophthalmology Times.
Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.
According to Alcon, as CMO, Terry Kim, MD, will continue to integrate scientific and clinical priorities across Alcon’s Surgical and Vision Care franchises, with a focus on meeting the needs of patients and eye care practitioners across the globe.
The NOVA clinical trial has found statistical non-inferiority to current clinical standards for sensitivities at individual test locations, glaucoma staging using Medicare definitions, and an exceptionally high correlation of 0.94 in mean deviation.
Stargardt disease is the most common inherited retinal dystrophy (causing blurring or loss of central vision) in both adults and children.
The new cohort will add patients living with IRDs caused by mutations in multiple genes to the already existing cohort of patients with IRDs caused by single gene mutations.
The positive opinion concerns authorization of bevacizumab gamma (ONS-5010/LYTENAVA), a formulation of bevacizumab for treatment of wet age-related macular degeneration (wet AMD).
Conference defines the future of anterior segment surgery.
